Evaluation of the proliferation marker MIB‐1 in the prognosis of cutaneous malignant melanoma
Open Access
- 23 July 2002
- Vol. 95 (3) , 634-640
- https://doi.org/10.1002/cncr.10685
Abstract
BACKGROUND: The proliferation marker MIB‐1, which recognizes the Ki‐67 antigen, provides independent prognostic information in several tumor types. Its utility in melanoma has been evaluated mostly in studies of thick primary tumors. Its usefulness in thinner lesions has not been assessed adequately.METHODS: A well characterized cohort of 137 patients diagnosed with primary cutaneous melanoma at the New York University School of Medicine between 1972 and 1982 was studied based on the availability of representative tissues and adequate clinical follow‐up. Twenty‐one tumors were less than or equal to 1.0 mm thick, 94 were between 1.01 and 4.0 mm thick, and 22 were thicker than 4.0 mm. Tumor cell proliferation was assessed by immunohistochemistry using the monoclonal antibody MIB‐1. MIB‐1 expression was correlated with baseline clinicopathologic parameters, as well as recurrence (RR), disease‐free (DFS), and overall survival (OS) rates. Median follow‐up among survivors was 6.5 years (range, 5.6–17.5).RESULTS: High proliferative index, defined as 20% or more of tumor cells showing nuclear immunoreactivity, was observed in 65 of 137 (47.4%) cases. High proliferative index was significantly correlated with increased tumor thickness (P< 0.001) and higher stage (P= 0.03). Trends approaching statistical significance were observed with ulceration of the primary tumor (P= 0.09), male gender (P= 0.06), and shorter DFS (P= 0.12). No significant associations were seen between high proliferative index and RR or OS. In multivariate analyses, tumor thickness was the strongest predictor of clinical outcome.CONCLUSIONS: In primary cutaneous melanoma, a high proliferative index is associated with clinicopathologic parameters predictive of worse clinical outcomes. However, it was not an independent predictor of clinical outcome. Cancer 2002;95:634–40. © 2002 American Cancer Society.DOI 10.1002/cncr.10685Keywords
This publication has 26 references indexed in Scilit:
- The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanomaCancer, 2001
- Predicting five-year outcome for patients with cutaneous melanoma in a population-based studyCancer, 1996
- Nuclear morphometry, immunohistochemical staining with Ki‐67 antibody and mitotic index in the assessment of proliferative activity and prognosis of primary malignant melanomas of the skinJournal of Cutaneous Pathology, 1996
- MIB-1 Proliferative Activity Is a Significant Prognostic Factor in Primary Thick Cutaneous MelanomasJournal of Investigative Dermatology, 1995
- Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of clark's level for prognostic classificationCancer, 1995
- An application of MIB antibody to the retrospective study of melanomas of oral mucosa and facial skinZeitschrift für Krebsforschung und Klinische Onkologie, 1994
- Clinical and Histopathologic Predictors of Survival in Patients With Malignant Melanoma: a Population-Based Study in SwedenJNCI Journal of the National Cancer Institute, 1994
- Multivariate analysis of the relationship between survival and the microstage of primary melanoma by clark level and breslow thicknessCancer, 1993
- The annual risk of melanoma progression. Implications for the concept of cureCancer, 1992
- Model Predicting Survival in Stage I Melanoma Based on Tumor ProgressionJNCI Journal of the National Cancer Institute, 1989